Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of LYB001 Heterologous Booster in Adults
NCT05928455Phase 1Unknown
- Sponsor
- Patronus Biotech
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of recombinant sars-cov-2 vaccine (cho cell) lyb001 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Patronus Biotech. Primary endpoints: Seroconversion of neutralizing antibodies at 28 days, Seroconversion of S protein-binding antibodies at 28 days and 4 more. Status: unknown.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05928455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928455.